CYRX - CryoPort Inc Stock Price, Fair Value and News

12.67USD-0.99 (-7.25%)Market Closed

Market Summary

USD12.67-0.99

Market Closed

-7.25%

CYRX Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

CYRX Stock Price

View Fullscreen

CYRX RSI Chart

CYRX Valuation

Market Cap

624.1M

Price/Earnings (Trailing)

-5.43

Price/Sales (Trailing)

2.77

EV/EBITDA

-12.06

Price/Free Cashflow

-15.6

CYRX Price/Sales (Trailing)

CYRX Profitability

Operating Margin

41.79%

EBT Margin

-50.19%

Return on Equity

-24.34%

Return on Assets

-12.19%

Free Cashflow Yield

-6.41%

CYRX Fundamentals

CYRX Revenue

Revenue (TTM)

225.0M

Rev. Growth (Yr)

-13.09%

Rev. Growth (Qtr)

-4.66%

CYRX Earnings

Earnings (TTM)

-114.9M

Earnings Growth (Yr)

-274.87%

Earnings Growth (Qtr)

66.51%

Breaking Down CYRX Revenue

Last 7 days

-4.9%

Last 30 days

-24.5%

Last 90 days

-19.2%

Trailing 12 Months

-36.4%

How does CYRX drawdown profile look like?

CYRX Financial Health

Current Ratio

10.73

Debt/Equity

0.8

Debt/Cashflow

-0.02

CYRX Investor Care

Shares Dilution (1Y)

8.15%

Diluted EPS (TTM)

-2.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	225.0M	0	0	0
2023	247.8M	240.7M	236.4M	233.3M
2022	225.5M	231.4M	234.3M	237.3M
2021	122.2M	169.0M	214.5M	222.6M
2020	37.1M	38.0M	39.6M	78.7M
2019	22.3M	26.1M	30.4M	33.9M
2018	13.3M	15.0M	17.3M	19.6M
2017	8.8M	9.8M	10.9M	12.0M
2016	5.9M	6.4M	6.9M	7.7M
2015	4.3M	4.8M	5.4M	5.9M
2014	2.7M	3.1M	3.4M	3.6M
2013	1.1M	1.4M	1.7M	2.2M
2012	555.6K	622.9K	746.2K	908.9K
2011	475.5K	447.8K	434.1K	478.8K
2010	118.0K	207.3K	296.7K	386.1K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of CryoPort Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	stefanovich robert	sold	-18,928	17.5423	-1,079	chief financial officer
Mar 25, 2024	shelton jerrell	sold	-46,153	17.5423	-2,631	chief executive officer
Mar 25, 2024	sawicki mark w	sold	-23,980	17.5423	-1,367	chief scientific officer
Mar 15, 2024	sawicki mark w	acquired	-	-	5,750	chief scientific officer
Mar 15, 2024	shelton jerrell	acquired	-	-	14,901	president, ceo
Mar 15, 2024	zecchini edward j	acquired	-	-	10,455	chief digital and tech officer
Mar 15, 2024	sawicki mark w	sold	-20,247	15.4322	-1,312	chief scientific officer
Mar 15, 2024	shelton jerrell	sold	-872,884	15.3033	-57,039	president, ceo
Mar 15, 2024	stefanovich robert	acquired	-	-	5,750	chief financial officer
Mar 15, 2024	mandalam ramkumar	acquired	45,003	5.4	8,334	-

Which funds bought or sold CYRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-32.39	-125,096	424,907	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.47	71,846	856,291	-%
May 16, 2024	COMERICA BANK	added	73.01	30,422	61,594	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	81.45	1,907,930	3,685,440	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-27.5	-503,833	2,432,530	-%
May 15, 2024	Blackstone Inc.	unchanged	-	1,002,000	8,025,110	0.03%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	1,021,290	1,021,290	0.01%
May 15, 2024	PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO	unchanged	-	14,000	108,000	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	313	2,513	-%
May 15, 2024	Bayesian Capital Management, LP	sold off	-100	-362,466	-	-%

Are Funds Buying or Selling CYRX?

Are funds buying CYRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYRX

No. of Funds

Unveiling CryoPort Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cadian capital management, lp	7.1%	34,640	SC 13G
Feb 14, 2024	brown capital management llc	13.79%	6,754,317	SC 13G/A
Feb 14, 2024	alger associates inc	4.1%	1,989,100	SC 13G/A
Feb 13, 2024	vanguard group inc	7.47%	3,657,661	SC 13G/A
Feb 08, 2024	morgan stanley	8.5%	4,141,522	SC 13G
Jan 26, 2024	blackrock inc.	7.3%	3,568,644	SC 13G/A
Feb 14, 2023	brown capital management llc	14.20%	6,959,207	SC 13G/A
Feb 14, 2023	alger associates inc	5.6%	2,720,035	SC 13G/A
Feb 09, 2023	vanguard group inc	7.21%	3,535,073	SC 13G/A
Feb 08, 2023	invesco ltd.	1.8%	904,984	SC 13G/A

Recent SEC filings of CryoPort Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 15, 2024	144	Notice of Insider Sale Intent
May 15, 2024	4	Insider Trading
May 08, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 03, 2024	DEF 14A	DEF 14A
Apr 03, 2024	DEFA14A	DEFA14A
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading

Peers (Alternatives to CryoPort Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
FDX	63.3B	87.5B	-2.21%	11.64%	14.4	0.72	-5.51%	46.89%
GWW	46.4B	16.6B	-0.47%	39.19%	25.37	2.79	6.06%	9.62%
FAST	38.0B	7.4B	-2.99%	20.26%	32.85	5.15	3.46%	4.06%
JBHT	17.0B	12.5B	-2.04%	-3.51%	25.84	1.36	-13.82%	-28.77%
EXPD	16.7B	8.9B	3.13%	2.83%	23.93	1.87	-40.57%	-43.75%
MID-CAP
CHRW	9.8B	17.4B	22.22%	-17.13%	32.49	0.57	-22.65%	-61.39%
KNX	7.9B	7.3B	1.26%	-10.96%	72.05	1.08	1.23%	-83.48%
AIT	7.6B	4.5B	6.84%	51.37%	20.31	1.7	3.72%	12.24%
BECN	6.1B	9.3B	3.20%	46.41%	14.71	0.66	9.73%	-2.71%
ARCB	2.7B	4.4B	-18.73%	30.53%	21.88	0.61	-10.46%	-59.38%
SMALL-CAP
BXC	873.9M	3.1B	-8.28%	16.64%	18.12	0.29	-22.33%	-73.30%
CYRX	624.1M	225.0M	-24.54%	-36.43%	-5.43	2.77	-9.19%	-264.75%
CVLG	607.8M	1.1B	6.29%	18.92%	14.28	0.54	-6.43%	-58.73%
DSKE	391.3M	1.6B	-0.12%	0.61%	-22.11	0.25	-11.50%	-135.26%
AIRT	64.9M	220.4M	2.77%	-16.00%	-5.97	0.29	16.77%	-270.60%

CryoPort Inc News

Latest updates

CryoPort Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-4.7%	54,592,000	57,260,000	56,157,000	57,021,000	62,817,000	60,358,000	60,464,000	64,153,000	52,302,000	54,371,000	56,440,000	56,693,000	56,191,000	53,284,000	48,361,000	11,172,000	9,389,000	9,774,000	9,242,000	9,583,000	8,464,000
Cost Of Revenue	-3.5%	32,817,000	33,999,000	31,891,000	32,288,000	35,745,000	34,081,000	34,047,000	35,315,000	29,961,000	-	33,327,500	33,180,000	30,789,000	28,734,000	28,467,000	5,117,000	4,262,000	4,516,000	4,309,513	4,956,277	4,125,199
Gross Profit	-6.4%	21,775,000	23,261,000	24,266,000	24,733,000	27,072,000	26,277,000	26,417,000	28,838,000	22,341,000	-	23,113,000	23,513,000	25,402,000	24,550,000	19,894,000	6,055,000	5,127,000	5,258,000	4,932,000	4,627,000	4,338,000
Operating Expenses	-53.8%	43,056,000	93,132,000	41,175,000	43,065,000	37,117,000	37,312,000	34,220,000	34,085,000	30,160,000	-	31,475,500	28,089,000	29,150,000	25,692,000	29,739,500	16,788,000	10,973,000	8,844,000	5,810,959	16,978,807	6,642,787
S&GA Expenses	-1.3%	38,304,000	38,814,000	36,023,000	38,802,000	33,241,000	32,635,000	30,235,000	30,563,000	26,622,000	-	27,586,000	23,901,000	24,688,000	21,388,000	26,247,000	14,476,000	9,026,000	7,111,000	20,073,342	5,961,593	2,843,073
R&D Expenses	0.1%	4,752,000	4,749,000	5,152,000	4,263,000	3,876,000	4,677,000	3,985,000	3,522,000	3,538,000	-	3,889,500	4,188,000	4,462,000	4,304,000	3,492,500	2,312,000	1,947,000	1,733,000	1,069,943	1,640,528	540,933
EBITDA Margin	-23.5%	-0.35	-0.28	-0.05	-0.02	0.01	-0.03	-1.11	-1.13	-1.13	-1.10	-1.12	0.01	-	-	-	-	-	-	-	-	-
Interest Expenses	2.5%	1,338,000	1,306,000	1,357,000	1,331,000	1,509,000	1,456,000	1,609,000	1,586,000	1,491,000	-	1,126,000	1,189,000	1,164,000	1,210,000	270,500	1,889,000	398,000	2,000	445,952	248,410	333,910
Income Taxes	115.8%	215,000	-1,359,000	471,000	635,000	492,000	1,477,000	57,000	364,000	341,000	-	-875,500	1,024,000	499,000	1,038,000	-99,000	-29,000	50,000	33,000	51,390	1,886	9,624
Earnings Before Taxes	70.7%	-18,680,000	-63,748,000	-12,798,000	-17,720,000	-5,082,000	-7,959,000	-5,259,000	-8,813,000	-13,063,000	-	-260,961,500	-5,502,000	-4,890,000	-2,489,000	-11,628,500	-11,447,000	-5,753,000	-3,909,000	-896,670	-12,466,661	-2,518,867
EBT Margin	-17.8%	-0.50	-0.43	-0.18	-0.15	-0.11	-0.15	-1.23	-1.25	-1.24	-1.21	-1.23	-0.11	-	-	-	-	-	-	-	-	-
Net Income	66.5%	-20,895,000	-62,389,000	-13,269,000	-18,355,000	-5,574,000	-11,436,000	-5,316,000	-9,177,000	-13,404,000	-	-262,086,000	-8,526,000	-7,389,000	-5,723,000	-53,866,000	-11,418,000	-5,803,000	-3,943,000	-948,000	-12,469,000	-2,528,000
Net Income Margin	-19.6%	-0.51	-0.43	-0.21	-0.17	-0.13	-0.17	-1.24	-1.27	-1.28	-1.26	-1.27	-0.35	-	-	-	-	-	-	-	-	-
Free Cashflow	20.0%	-7,271,000	-9,091,000	-10,928,000	-12,728,000	-6,795,000	-4,203,000	-4,208,000	-11,826,000	-3,721,000	-5,712,000	-5,712,000	25,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.6%	943	958	1,001	1,031	1,048	1,039	1,034	1,046	1,081	1,113	824	825	820	552	252	253	140	136	135	133	60.00
Current Assets	-1.8%	526	535	549	585	605	604	609	626	666	694	410	412	420	147	213	217	105	103	102	102	52.00
Cash Equivalents	7.2%	50.00	46.00	59.00	67.00	39.00	37.00	31.00	37.00	134	139	44.00	60.00	85.00	37.00	162	44.00	51.00	47.00	45.00	81.00	33.00
Inventory	-4.5%	25.00	26.00	29.00	29.00	26.00	28.00	25.00	23.00	22.00	17.00	13.00	12.00	12.00	11.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00
Net PPE	1.4%	86.00	85.00	75.00	69.00	71.00	64.00	58.00	54.00	51.00	49.00	43.00	38.00	32.00	30.00	15.00	14.00	12.00	12.00	11.00	10.00	5.00
Goodwill	-0.8%	108	108	149	149	152	151	151	145	147	147	24.00	3.00	141	145	106	11.00	11.00	11.00	11.00	11.00	-
Liabilities	0.4%	471	469	463	486	488	483	478	478	472	471	177	177	172	170	132	126	13.00	10.00	25.00	24.00	21.00
Current Liabilities	7.4%	49.00	46.00	45.00	40.00	42.00	41.00	41.00	44.00	44.00	43.00	41.00	38.00	38.00	35.00	13.00	9.00	7.00	5.00	6.00	6.00	5.00
Long Term Debt	0.2%	379	379	378	408	407	407	406	405	405	404	112	112	112	111	111	111	-	-	15.00	15.00	15.00
LT Debt, Non Current	-100.0%	-	379	378	408	407	407	406	405	405	404	112	112	112	111	111	111	-	-	15.00	15.00	15.00
Shareholder's Equity	-3.4%	472	489	538	544	561	556	556	568	609	642	647	648	647	383	120	127	127	126	110	109	39.00
Retained Earnings	-2.9%	-661	-642	-580	-566	-548	-542	-503	-498	-489	-467	-207	-200	-195	-192	-180	-169	-163	-159	-158	-145	-143
Additional Paid-In Capital	0.4%	1,135	1,131	1,127	1,123	1,118	1,115	1,086	1,082	1,103	1,100	846	842	838	566	300	295	290	286	269	255	182
Shares Outstanding	0.6%	49.00	49.00	49.00	49.00	49.00	48.00	49.00	49.00	50.00	46.00	46.00	45.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	500	-	-	-	1,100	-	-	-	-	-	-	-	2.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-231.5%	-3,265	2,482	-1,959	-4,054	2,774	3,654	982	-7,011	524	2,614	8,876	2,627	-5,991	-9,712	-4,844	-1,369	1,059	741	-813	-1,061	-189
Share Based Compensation	-6.7%	5,456	5,848	5,976	5,800	5,184	5,333	5,366	5,258	4,125	4,182	4,148	4,025	2,990	2,561	2,433	2,302	1,620	1,611	1,946	1,992	1,414
Cashflow From Investing	143.7%	6,445	-14,760	18,510	33,678	-1,383	7,124	-5,865	-63,990	3,050	-195,971	-27,008	-30,905	-215,370	-383,060	120,338	-119,048	-542	790	-36,645	-21,419	-5,651
Cashflow From Financing	506.3%	512	-126	-24,891	1,148	71.00	-5,306	-459	-25,360	-8,049	288,575	2,491	1,883	271,393	266,443	2,151	114,127	2,864	1,093	1,410	70,357	1,290
Buy Backs	-	-	-	-	-	-	4,611	-	25,000	8,349	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CYRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 54,592	$ 62,817
Total cost of revenue	32,817	35,745
Gross margin	21,775	27,072
Operating costs and expenses:
Selling, general and administrative	38,304	33,241
Engineering and development	4,752	3,876
Total operating costs and expenses	43,056	37,117
Loss from operations	(21,281)	(10,045)
Other income (expense):
Investment income	2,600	2,467
Interest expense	(1,338)	(1,509)
Other income, net	1,339	4,005
Total other income, net	2,601	4,963
Loss before provision for income taxes	(18,680)	(5,082)
Provision for income taxes	(215)	(492)
Net loss	(18,895)	(5,574)
Paid-in-kind dividend on Series C convertible preferred stock	(2,000)	(2,000)
Net loss attributable to common stockholders	$ (20,895)	$ (7,574)
Net loss per share - basic (in dollar per share)	$ (0.43)	$ (0.16)
Net loss per share - diluted (in dollar per share)	$ (0.43)	$ (0.16)
Weighted average shares outstanding - basic (in shares)	49,019,964	48,362,501
Weighted average shares outstanding - diluted (in shares)	49,019,964	48,362,501
Life Sciences Services
Total revenue	$ 36,786	$ 35,836
Total cost of revenue	21,602	19,076
Life Sciences Products
Total revenue	17,806	26,981
Total cost of revenue	$ 11,215	$ 16,669

CYRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 49,663	$ 46,346
Short-term investments	398,881	410,409
Accounts receivable, net	41,253	42,074
Inventories	25,020	26,206
Prepaid expenses and other current assets	10,887	10,077
Total current assets	525,704	535,112
Property and equipment, net	86,008	84,858
Operating lease right-of-use assets	31,029	32,653
Intangible assets, net	190,088	194,382
Goodwill	107,588	108,403
Deposits	1,674	1,680
Deferred tax assets	758	656
Total assets	942,849	957,744
Current Liabilities:
Accounts payable and other accrued expenses	27,376	26,995
Accrued compensation and related expenses	14,062	11,409
Deferred revenue	1,777	1,308
Current portion of operating lease liabilities	5,356	5,371
Current portion of finance lease liabilities	301	286
Current portion of notes payable	110	149
Current portion of contingent consideration		92
Total current liabilities	48,982	45,610
Convertible senior notes, net of discount of $6.4 million and $7.0 million, respectively	379,153	378,553
Notes payable	1,305	1,335
Operating lease liabilities, net of current portion	27,798	29,355
Finance lease liabilities, net of current portion	916	954
Deferred tax liabilities	2,414	2,816
Other long-term liabilities	312	601
Contingent consideration, net of current portion	9,779	9,497
Total liabilities	470,659	468,721
Commitments and contingencies
Stockholders' Equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized:
Common stock, $0.001 par value; 100,000,000 shares authorized; 49,256,794 and 48,971,026 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	49	49
Additional paid-in capital	1,135,257	1,131,183
Accumulated deficit	(661,314)	(642,419)
Accumulated other comprehensive loss	(30,077)	(26,065)
Total stockholders' equity	472,190	489,023
Total liabilities and stockholders' equity	942,849	957,744
Class A convertible preferred stock
Stockholders' Equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized:
Class B convertible preferred stock
Stockholders' Equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized:
Class C convertible preferred stock
Stockholders' Equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized:	$ 28,275	$ 26,275

About CryoPort Inc

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80Ã‚Â°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20Ã‚Â°C and -150Ã‚Â°C. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

CEO	Mr. Jerrell W. Shelton
WEBSITE	cryoport.com
INDUSTRY	Integrated Freight & Logistics
EMPLOYEES	1000

CryoPort Inc Frequently Asked Questions

What is the ticker symbol for CryoPort Inc? What does CYRX stand for in stocks?

CYRX is the stock ticker symbol of CryoPort Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CryoPort Inc (CYRX)?

As of Fri May 17 2024, market cap of CryoPort Inc is 624.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYRX stock?

You can check CYRX's fair value in chart for subscribers.

What is the fair value of CYRX stock?

You can check CYRX's fair value in chart for subscribers. The fair value of CryoPort Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CryoPort Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CryoPort Inc a good stock to buy?

The fair value guage provides a quick view whether CYRX is over valued or under valued. Whether CryoPort Inc is cheap or expensive depends on the assumptions which impact CryoPort Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYRX.

What is CryoPort Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CYRX's PE ratio (Price to Earnings) is -5.43 and Price to Sales (PS) ratio is 2.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CryoPort Inc's stock?

In the past 10 years, CryoPort Inc has provided 0.445 (multiply by 100 for percentage) rate of return.